MAST CELL ACTIVATION SYNDROME (MCAS) DIFFERENTIAL DIAGNOSIS

View at publisher Summarise with VIRAT
Authors: YAĞMUR ÖZKAN, Mehmet Halil Çelıksoy
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Mast cell activation syndrome (MCAS) is characterized by multisystem clinical manifestations re-sulting from systemic mast cell activation, presenting with recurrent anaphylaxis-like episodes and requiring fulfillment of three diagnostic criteria. These include the presence of mast cell–mediated symptoms involving more than one organ system, a concurrent increase in laboratory markers, particu-larly serum tryptase, and demonstrable clinical improvement with mast cell–directed therapies. MCAS is classified according to its underlying pathogenesis into primary (clonal), secondary (IgE-mediated hypersensitivity related), and idiopathic forms. Additional subtypes, such as hereditary alpha-trypt-asemia (HAT)–associated MCAS and mixed-type MCAS, have also been described in recent litera-ture. According to the terminology proposed by the ECNM–AIM (European Competence Network on Mastocytosis–American Initiative in Mast Cell Diseases) consortium, MCAS falls under the umbrella of mast cell activation disorders (MCADs). Patients who do not fulfill all three MCAS criteria but demonstrate objective evidence of mast cell activation are classified as ‘other MCADs.’ Conversely, in cases where mast cell–mediated mechanisms are excluded and MCAS criteria are not met, a systematic differential diagnostic evaluation is recommended. In patients presenting with chronic, nonspecific, or organ-limited symptoms such as flushing, pruritus, tachycardia, or abdominal pain, MCAS criteria are typically not fulfilled. Alternative diagnoses, including allergic reactions, food intolerance, adverse drug effects, autoimmune diseases, infections, cardiovascular or endocrine emergencies, toxin expo-sure, and psychiatric conditions should be considered. An increase in serum tryptase of 20% + 2 ng/mL above baseline during acute episodes remains the most reliable biochemical marker; however, elevated tryptase may also be seen in HAT, chronic kidney disease, hypereosinophilic syndromes, and myeloid neoplasms, requiring clinical context for interpretation. HAT, caused by increased copy numbers of the TPSAB1 gene, results in elevated baseline alpha-tryptase and is relatively common in the general population. It may predispose to MCAS-like symptoms and act as a genetic modifier increasing the fre-quency and severity of mast cell–mediated anaphylaxis. HAT has also been reported in association with Ehlers-Danlos syndrome (EDS) and postural orthostatic tachycardia syndrome (POTS). Although mast cell–related mechanisms have been proposed as a shared pathway among MCAS, EDS, and POTS, a definitive causal relationship has not been established.

Fields of Study & Subjects

Mast cells and histamine Food Allergy and Anaphylaxis Research Drug-Induced Adverse Reactions

Publication details

Journal / source
Turkiye Klinikleri eBooks
Pages
275–283
Publication date
1 January 2026
Language
EN
Document type
Book chapter